Treatment with inhibitors of BCLX such as ABT-263 was demonstrated to cause thrombocytopenia due to their neutralization of BCLXL in circulating platelets without bone marrow toxicity [30,63,64]. This evidence concerns the gene BCL2L1 and Thrombocytopenia.